I posed this question to Lopsided regarding the logistics of the packaging of this combination medication , but if anybody with experience in Big Pharma has any thoughts, I'd appreciate hearing them.

Quote:

---

"Lopsided, you could be the best person to answer, how, the combined company could combine these 2 separate sub-cutaneous injections, one of which needs to be injected weekly for however long until CTCs and CAMLs are less than a given threshold for say (2) consecutive months, at which point, the 1st sub-cutaneous injection is stopped and the second sub-cutaneous injection is begun to be administered weekly until the appropriate imaging tests state that there is no evidence of disease or that the disease is no longer progressing.

Would the prescribing physician prescribe each drug individually and instruct the patient as to when to stop the leronlimab and when to begin the PD-1 blocker?

What about the scenairio where the treating physician prescribes leronlimab and the PD-1 blocker separately? That would give him the freedom to choose any PD-1 blocker.

I think that is possible, but then CytoDyn would need to do the appropriate clinical trial."

---